



M 3 59148 04670 9

NDC 59148-046-70 Rx ONLY
DACOGEN.
decitabine for injection
50 mg per vial

FOR INTRAVENOUS INFUSION ONLY

WARNING: Cytotoxic Agent
Single-dose sterile vial - discard
unused portion.

Store vials at 20°C to 25°C
(68°F to 77°F); excursions permitted
between 15°C to 30°C (59°F to 86°F)
[See USP Controlled Room Temperature].

Each vial contains 50 mg decitabine,
68 mg monobasic potassium
phosphate, and 11.6 mg sodium
hydroxide. Sodium hydroxide and/or
hydrochloric acid are used for
pH adjustment. See package
insert and/or carton for detailed
indications, reconstitution
information, dosage information,
and precautions.



Pfizer
BioSila America Pharmaceutical, Inc.

Dacogen® is a registered trademark of
Astellas Pharmaceuticals, Inc.
used under license.

516616XX

EXP: MMM YYYY
LOT: XXXXXXXX

DACOGEN[®]
decitabine for injection
50 mg per vial

NDC 59148-046-70

DACOGEN[®]
decitabine for injection
50 mg per vial

FOR INTRAVENOUS INFUSION ONLY

WARNING: Cytotoxic Agent

Single-dose sterile vial - discard
unused portion.

Rx ONLY

Storage: Store vials at 20°C to 25°C
(68°F to 77°F); excursions permitted
between 15°C to 30°C (59°F to 86°F)
[See USP Controlled Room Temperature].



Otsuka
Otsuka America Pharmaceutical, Inc.

NDC 59148-046-70

See bottom flap for lot number
and expiration date.

KEEP THIS AND ALL MEDICATIONS
OUT OF THE REACH OF CHILDREN.

Manufactured by Pharmachemie B.V.
Haarlem, The Netherlands

Manufactured for
Otsuka America Pharmaceutical, Inc.
Rockville, MD 20850 USA

Dacogen[®] is a registered trademark of
Astex Pharmaceuticals, Inc.
used under license.



NDC 59148-046-70

DACOGEN[®]
decitabine for injection
50 mg per vial

FOR INTRAVENOUS INFUSION ONLY

WARNING: Cytotoxic Agent

Single-dose sterile vial - discard
unused portion.

Rx ONLY

Storage: Store vials at 20°C to 25°C
(68°F to 77°F); excursions permitted
between 15°C to 30°C (59°F to 86°F)
[See USP Controlled Room Temperature].



Otsuka
Otsuka America Pharmaceutical, Inc.

Each vial contains 50 mg decitabine, 68 mg
monobasic potassium phosphate, and
11.6 mg sodium hydroxide. Sodium hydroxide
and/or hydrochloric acid are used for
pH adjustment.

Reconstitution: Aseptically reconstitute
with 10 mL of Sterile Water for Injection, USP;
each mL will contain 5 mg of decitabine.
Further dilution is required. See package
insert.

Final Concentration: The resultant solution
will have a 5 mg per mL (5 mg/mL)
concentration and pH of 6.7 to 7.3.

Stability: Unless used within 15 minutes
of reconstitution, the diluted solution must
be prepared using cold (2°C to 8°C) infusion
fluids and stored at 2°C to 8°C (36°F to 46°F)
for up to a maximum of 4 hours until
administration.

See package insert for detailed indications,
reconstitution information, dosage
information, and precautions.



Otsuka
Otsuka America Pharmaceutical, Inc.

516615XX



GTIN: 00359148000000
SN: 10000000001
EXP: MMM YYYY
LOT: XXXXXXXX